{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6"],"submitter":["Chen W"],"pubmed_abstract":["We determined the mitogen-activated protein kinase (MAPK) gene expression profile of acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed to identify c-Jun as an important molecule mediating the efficacy of sorafenib. Differences in gene expression of the MAPK signaling between untreated and sorafenib-treated HCC cell lines were investigated using real-time polymerase chain reaction array. Western blot and real-time PCR further evaluated the expression of c-Jun. Pathological specimens from 50 patients with advanced HCC were collected to measure p-c-Jun expression. Sorafenib-resistant HCC cells demonstrated greater levels of basal c-Jun mRNA and protein compared with sorafenib-sensitive HCC cells. Sorafenib activated p-c-Jun in a dose- and time-dependent"],"journal":["Scientific reports"],"pagination":["22976"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4786823"],"repository":["biostudies-literature"],"pubmed_title":["Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence."],"pmcid":["PMC4786823"],"pubmed_authors":["Yin X","Lai J","Zhang K","Chen W","Xiao W","Liang L","Chen D"],"additional_accession":[]},"is_claimable":false,"name":"Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.","description":"We determined the mitogen-activated protein kinase (MAPK) gene expression profile of acquired resistance in sorafenib-sensitive hepatocellular carcinoma (HCC) cells and aimed to identify c-Jun as an important molecule mediating the efficacy of sorafenib. Differences in gene expression of the MAPK signaling between untreated and sorafenib-treated HCC cell lines were investigated using real-time polymerase chain reaction array. Western blot and real-time PCR further evaluated the expression of c-Jun. Pathological specimens from 50 patients with advanced HCC were collected to measure p-c-Jun expression. Sorafenib-resistant HCC cells demonstrated greater levels of basal c-Jun mRNA and protein compared with sorafenib-sensitive HCC cells. Sorafenib activated p-c-Jun in a dose- and time-dependent","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Mar","modification":"2025-04-18T22:04:00.069Z","creation":"2019-03-27T02:10:52Z"},"accession":"S-EPMC4786823","cross_references":{"pubmed":["26964667"],"doi":["10.1038/srep22976"]}}